Evidence map›Paper›PMID 41986807›Full record

ArticleHepatology international2026

Impact of pharmacological sGC stimulation with Riociguat in experimental models of liver disease regression.

Katharina Bonitz, Philipp Königshofer, Henriette Horstmeier, Thomas Sorz-Nechay, Vlad Taru, Katharina Bareiner, Oleksander Petrenko, Benedikt Simbrunner, Benedikt Silvester Hofer, Georg Kramer and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Katharina BonitzDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Philipp KönigshoferDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Henriette HorstmeierDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Thomas Sorz-NechayDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Vlad TaruDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Katharina BareinerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Oleksander PetrenkoDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Benedikt SimbrunnerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Benedikt Silvester HoferDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Georg KramerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Katja SommerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Kerstin ZinoberDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Katharina RegnatDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Hubert ScharnaglClinical Institute of Medical and Chemical Laboratory Diagnostics, Graz, Austria.
Peng SunCardioRenalMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach an Der Riss, Germany.
Eric SimonComputational Innovation, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach an Der Riss, Germany.
Stefan KausckeCardioRenalMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach an Der Riss, Germany.
Michael TraunerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Thomas ReibergerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.reiberger@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-4590-3583
Philipp SchwablDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver fibrosis and portal hypertension (PH) determine prognosis in chronic liver disease. In experimental models, stimulation of NO-sGC-cGMP signaling improved fibrosis, PH and inflammation. Since fibrosis and PH improve slowly after injury cessation, we investigated whether stimulating sGC activity accelerates their regression.

methodsLiver fibrosis was induced in C57BL/6 J mice by either carbon tetrachloride (CCl

resultsPH and fibrosis area peaked in the TAA model at 7.71 ± 0.57 mmHg PP and 3.87 ± 0.19% CPA; and in the CCl

conclusionsRiociguat increases hepatic cGMP bioavailability and mitigates inflammatory and metabolic gene signatures in two experimental models of regressive liver disease. While regression of liver fibrosis and PH was not accelerated by Riociguat, our results suggest beneficial effects of sGC stimulation during regressive liver disease.

Indexed as

Experimental fibrosisLiver fibrosis regressionLiver transcriptomicsPortal hypertensionRiociguatSoluble guanylyl cyclase

Identifiers

PMID41986807

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.